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When a clinical trial of an analgesic produces a negative ﬁnding, it is important to consider the inﬂuence
(if any) of experimental error on the validity of that result. Although efforts to identify and minimize
experimental error in chronic pain investigations have begun in earnest, less work has been performed
on the optimization of acute pain methodology. Of the acute surgical pain methodology articles that have
been published over the last decade, almost all focus on either the dental or bunion model. Analgesics are
typically evaluated in a variety of surgical models that eventually include hospital-based models (eg, joint
replacement and soft tissue surgery). Every surgical procedure has unique clinical characteristics that
must be considered to optimize study design and conduct. Much of the methodological knowledge gar-
nered from bunion and dental studies is applicable to other surgical models, but some extrapolations are
hazardous. The purposes of this review were (1) to qualitatively describe the clinical and experimental
characteristics of the 4 classic surgical models: dental extraction, bunionectomy, joint replacement,
and soft tissue surgery; and (2) to quantitatively compare the models by analyzing 3 factors: effect size,
enrollment rate, and demographics. We found that the dental extraction and bunionectomy models had
higher assay sensitivity than the joint replacement and soft tissue surgery models. It is probable that this
ﬁnding is secondary to the superior experimental conditions under which the dental and bunion models
are executed (utilization of few centers that have the ability to reduce surgical, anesthetic, and postop-
erative confounders).
 2013 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.1. Introduction
The high incidence of false-negative ﬁndings in analgesic inves-
tigations hinders the process of molecular discovery, increases the
cost of pharmaceutical development programs, and unnecessarily
burdens study participants by subjecting them to the dangers of
nonproductive research. Although several groups have initiated ef-
forts to identify factors that contribute to false-negative results in
chronic pain investigations [35–37,60], less attention has been fo-
cused on optimizing acute pain methodology. Over the past
20 years, most drug candidates indicated for the treatment of acute
pain have been opioid reformulations or reformulations of other
molecules with known analgesic efﬁcacy [62]. If one assumes that
reformulated drugs should generally demonstrate efﬁcacy in phase3, why are a signiﬁcant number of late-phase acute pain studies
negative [112–114]? When considering this question, it is impor-
tant to remember that drug efﬁcacy is not the only prerequisite
for a positive acute surgical analgesic trial; choice of surgical mod-
el, minimization of perioperative confounders, and control of sur-
gical/anesthetic variability also impact the likelihood of trial
success.
To test a drug in acute surgical pain, one must ﬁrst decide what
type of surgery will be utilized as a pain generator against which
the efﬁcacy of an investigational product will be measured. The
ideal surgical research model would have the following character-
istics: (1) produce a homogeneous and predictable pattern of pain
in a diverse population, (2) allow a range of experimental manipu-
lations that reliably alter the postoperative pain experience in or-
der to meet the needs of the experiment, (3) closely match the
clinical environment in which the agent will ultimately be admin-
istered, (4) include volunteers whose demographics are a represen-
tative sample of the target clinical population, (5) produce pain via
a well-understood physiological process, (6) be common enough so
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(7) allow state-of-the-art care to be provided in a manner that min-
imizes analgesic confounders. The clinical realities of a speciﬁc sur-
gical procedure and the degree to which these realities can be
ethically manipulated determine the potential of that procedure
to serve as an ideal research model.
Considering the variety and frequency of painful surgical inter-
ventions, one might imagine that there are many well-described,
high-quality surgical research models available to an investigator.
However, models that appear to be ideal but have not been scruti-
nized over time may have characteristics that are not yet under-
stood. Therefore, researchers generally make what they consider to
be a safe choice by selecting a classic surgical model that has been
widely utilized in previous analgesic investigations. The 4 classic
surgicalmodels are: dental impaction, bunionectomy, joint replace-
ment surgery (JRS), and soft tissue surgery (STS). Unfortunately,
mostof thepublished literatureon themethodologyof acutepain fo-
cuses either on the dental or the bunionmodel [20,22,69,93], forcing
design considerations in JRS and STS to be based on extrapolation.
Because JRS and STS are clinically distinct fromboth dental and bun-
ion surgery, thesemodels have unique experimental characteristics,
which as of yet are not well understood.
The purposes of this review were (1) to qualitatively describe the
clinical and experimental characteristics of the 4 classic surgical mod-
els and (2) to quantitatively examine each model in order to make
objective comparisons. The discussion of each of the 4 models is di-
vided into 5 sections: (1) introduction, (2) surgical and anesthesia pro-
tocol, (3) enrollment rate, (4) assay sensitivity, and (5) model
limitations. The ﬁrst 2 sections contain qualitative data only. Sections
3, 4, and 5 present quantitative results and relevant conclusions.
2. Methods
The procedures utilized to evaluate the investigation’s 3 quanti-
tative endpoints (standardized effect size [SES], enrollment rate, and
demographic characteristics) are described. All quantitative end-
points were ﬁrst subjected to a common primary set of inclusion/
exclusion (I/E) criteria. Subsequently, each of these 3 endpoints
was subjected to a unique set of secondary I/E criteria (Fig. 1).
2.1. Data sources
A systematic review of the literature using MEDLINE, PubMed,
the Cochrane library, andmanual search techniques was performedFig. 1. Study selection process for quantitatto identify prospective, double-blind, randomized, and controlled
clinical trials using analgesics for treatment of acute postoperative
pain. The detailed search strategy included subject headings and
MeSHterms ‘acutepain’, ‘randomized’, ‘placebo controlled’, ‘postop-
erative’, and ‘analgesics in adults’. The resulting list was intersected
with a group of terms relating to ‘bunionectomy’, ‘foot surgery’,
‘abdominal surgery’, ‘hysterectomy’, ‘hernia repair’, ‘total knee
arthroplasty’, ‘total hip replacement’, and ‘dental surgery’. Reference
lists,meta-analyses, US Food andDrugAdministration summaryba-
sis of approvals, and clinical trial register databases (clinicaltri-
al.gov) also were manually screened for relevant data. Titles and
abstracts ranging from1998 to the presentwere reviewed and inde-
pendently read by the authors (N.S. and P.D.C.) for eligibility accord-
ing to predeﬁned criteria.
2.2. Primary I/E criteria
Studies were included if they were: (1) primarily concerned
with the evaluation of acute surgical pain, (2) double-blind, (3)
placebo- or active-controlled, (4) randomized, (5) industry-spon-
sored, (6) written in English, (7) nonpediatric (deﬁned as age
>16 years), (8) of sufﬁcient size (deﬁned as at least 10 patients
per study arm), and (9) performed in 1 of the 4 surgical models rel-
evant to this investigation.
2.3. Secondary I/E criteria
For the SES endpoint, studies were included if they: (1) pre-
sented a continuous prespeciﬁed analgesic endpoint and (2) mea-
sured the effect of an active product against placebo. Studies were
excluded if they: (1) used only active comparators as controls, (2)
used devices to treat pain, (3) did not include sample size, (4) did
not explicitly provide treatment means (eg, provided data only in
graphical form), or (5) did not provide variance (eg, standard devi-
ation, standard error, or conﬁdence interval). The prespeciﬁed pri-
mary endpoint was used for the SES calculation preferentially. If
the primary endpoint was not one for which an SES could be calcu-
lated, a secondary endpoint pertaining to the assessment of pain
was utilized. If more than one secondary endpoint was provided,
the ﬁrst complete endpoint presented in the results section of the
article was selected. In studies in which various doses were exam-
ined, the effect size of the largest dose (vs placebo) was utilized.
For the enrollment rate endpoint, studies were included if they
disclosed: (1) the total number of enrolled subjects, (2) the numberive endpoints. I/E = inclusion/exclusion.
Fig. 2. Depiction of surgical characteristics within the dental model that can be
manipulated to alter the subject’s postoperative pain trajectory.
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tion dates. The date of study completion was deﬁned either as the
date that the ﬁnal subject received a perioperative intervention or
as the ﬁnal date on which data were collected. The former deﬁni-
tion was used preferentially. For the demographic endpoint, any
study that presented quantiﬁable demographic data was included.
2.4. Data synthesis
The SES for an individual study was determined by calculating
the ratio of the selected endpoint’s treatment effect to its pooled
standard deviation. Because SES can be positive or negative
depending on the nature of the endpoint, we assigned a positive
value to the SES when treatment outperformed placebo and a neg-
ative value when placebo outperformed treatment. SES was se-
lected as the critical outcome measure for this analysis because
it is a simple scale-free metric that is an accepted measure of an
investigation’s assay sensitivity (a numeric representation of an
experiment’s signal-to-noise ratio). Assay sensitivity is deﬁned as
the ability of a research study to detect a treatment difference
when the molecule being tested is in fact efﬁcacious.
SES ¼ ðMean of treatment group—Mean of placebo groupÞ
Pooled standard deviation
Recruitment rates were calculated by dividing the total number of
subjects enrolled in a particular study by both the number of
months it took for study completion and the number of participat-
ing sites (enrolled subjects/center/month).3. Results
3.1. Dental surgical model
3.1.1. Introduction
The dental impaction model relies on postsurgical pain gener-
ated via the prophylactic or therapeutic extraction of third molars.
The model has been in widespread use for over 50 years, is well
characterized, and is frequently used to investigate the pharmaco-
dynamic properties of analgesic molecules (onset/offset, dose-re-
sponse, and potency) [20–22,26]. Because third molar surgery is
generally performed on an outpatient basis, there is a common
misperception that the postoperative pain course is mild, and as
such, the experimental model is appropriate only for low-potency
oral analgesics [21]. In fact, surgical protocols can be modiﬁed so
that the postoperative pain experience is severe enough to (1) al-
low discrimination of strong intravenous analgesics vs placebo
on a multiple-dose basis for up to 24 hours after surgery
[34,63,115] or (2) mild enough to evaluate weak oral analgesics
[17,81,84]. Efﬁcacy in the dental model is highly predictive of efﬁ-
cacy in later stage models. Barden et al., comparing dental with
nondental analgesic data available through the Cochrane Collabo-
ration, concluded that ‘‘a drug, which is an analgesic in one pain
context, will also be an analgesic in other contexts’’ [4].
3.1.2. Surgical and anesthetic protocol
Because the dental model has been well characterized, the rela-
tionship between initial surgical trauma and resultant acute post-
operative pain is understood. By varying the number (1 to 4),
location (mandibular vs maxillary) and impaction grade (erupted,
impacted by soft tissue, bony impaction) of protocol mandated
extractions, the researcher can match the postoperative pain tra-
jectory to the needs of the experiment ([22]) (Fig. 2).
The anesthetic protocol for third molar extraction is straightfor-
ward, requiring primarily short-acting local anesthetics
[16,31,40,58,80]. The use of systemic medications that have centralnervous system depressant activity can largely be avoided. The
ideal experimental condition allows subjects to experience moder-
ate to severe postoperative pain at a time when intraoperatively
administered agents are no longer inﬂuencing pain perception
[22]. Although this experimental ideal is achievable in the dental
model, anesthetic regimens for bunion surgery, JRS, and STS all re-
quire administration of at least some systemic concomitant medi-
cation [94,104,118]. Carryover effects of central nervous system
depressants into the postoperative efﬁcacy evaluation period
may reduce the assay sensitivity of the 3 nondental models [22].3.1.3. Enrollment rate
Enrollment into dental studies was the most rapid of all models
analyzed, averaging 63 subjects per center per month (Fig. 3). This
rate illustrates that dental recruitment is on average 3.2 times fas-
ter than bunionectomy, 16.2 times faster than JRS, and 26.4 times
faster than STS. To understand the dental model, one needs to
appreciate its ﬁnancial and logistical underpinnings. In most
circumstances, the dental surgery fee is paid for by the research
grant. Although this point may seem at ﬁrst to have little inﬂuence
over the scientiﬁc merit of the model, in fact there are important
implications. Remuneration of surgical fees provides an easily
understood beneﬁt for the subject and greatly facilitates subject
accrual. Consequently, subjects do not need to be pooled from var-
ious institutions to meet enrollment timelines. Each dental study
in our review required an average of only 2.2 centers to complete
enrollment, in contrast to 4.5, 10.9, and 18.4 centers for bunionec-
tomy, JRS, and STS, respectively (Tables 1–4).3.1.4. Assay sensitivity
The average SES in the dental model was 1.51; 64%, 122%, and
202% higher than bunionectomy, JRS, and STS, respectively
(Fig. 4). The high assay sensitivity demonstrated in the dental mod-
el is likely the result of the experimental conditions in which the
protocol is carried out. In general, these studies are performed
within standalone research units where attempts are made to con-
trol standard of care confounders (perioperative ice, use of ad-
juncts, time to oral intake) [22]. Utilizing few centers reduces the
number of surgeons and anesthesiologists involved with the clini-
cal trial, each of whom introduces variability.
The dental extraction itself is predicated on the subject consent-
ing to clinical trial participation. This is in contrast to the JRS and
STS models, in which the study protocol is an add-on feature of
the surgery that would have proceeded in a clinical environment
(eg, hospital) whether or not the subject had been enrolled in a re-
search study. The quid pro quo established by subsidizing the cost
of the dental surgery may lead to a more objective research rela-
Fig. 3. Enrollment rate by surgical model. Enrollment rate was determined as the number of subjects enrolled in an investigation per study center per month (subjects
enrolled/center/month). # = Number of studies used in the analysis. JRS = joint replacement surgery; STS = soft tissue surgery.
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sive preoperative interaction fosters a classic therapeutic relation-
ship between doctor and patient, which postoperatively may
hinder their ability to establish an objective relationship.
3.1.5. Model limitations
The primary limitation of the dental model is lack of generaliz-
ability. Positive results in the dental model have signiﬁcance in the
proof-of-concept sphere, but for most acute analgesics, regulators
and prescribing physicians will demand proof of efﬁcacy in scenar-
ios that more closely resemble those in which the drug will ulti-
mately be prescribed. Although when manipulated the model
may be painful enough to discriminate intravenous opioids, these
medications are not a standard of care for acute dental pain. When
performed in a clinical setting (not for research purposes), dental
surgery is an outpatient procedure involving predominantly
healthy, young adult subjects (Table 5). Copious local anesthetic
inﬁltration, nerve blocks, and adjunctive therapy (eg, ice and non-
steroidal anti-inﬂammatory drugs) minimize the perioperativeFig. 4. Standardized effect size by model. Numbers above bars represent the aver
SES = standardized effect size; JRS = joint replacement surgery; STS = soft tissue surgery.pain experience so that patients can be adequately treated with
outpatient oral analgesics [50].
3.2. Bunionectomy model
3.2.1. Introduction
The bunionectomy model relies on surgical pain generated from
the correction of hallux valgus deformities of the ﬁrst metatarsal
[69]. The pain is a result of the procedure’s requisite osteotomy
and less so secondary to soft tissue damage required to gain appro-
priate surgical exposure. As such, it is generally classiﬁed as a bone
pain model and has been frequently used to evaluate drugs that re-
duce the inﬂammatory response involved with periosteal disrup-
tion [29,32]. The model was developed in the early 2000s
primarily as a solution to a signiﬁcant shortcoming in the dental
model—the need for pain of an adequate duration to measure mul-
tiple-day efﬁcacy [9,109].
The model has good assay sensitivity for approximately
72 hours after the surgical insult [32,33,111], with mixed resultsage SES for each surgical model. # = Number of studies used in the analysis.
Table 1
Dental surgery standardized effect size and enrollment rate summary.
Sponsor Source Trial
identiﬁcation
Drug Drug
type
N Primary endpoint Standardized
effect size
Number
of sites
Duration of
study (months)
Enrollment rate
(subjects/center/
month)
AstraZeneca Hill 2006
[82]
AZD3582 NSAID 356 MPID 8 1.5293 1 – –
AstraZeneca Hill 2006
[82]
AZD3582 NSAID 341 MPID 8 0.5892 4 – –
Bayer NCT01495858 BAY98-7111 NSAID 267 Wake time after
sleep onset 10
– 2 2 66.75
Iroko Pharmaceuticals NCT00964431 Celecoxib NSAID 203 TOTPAR 8 1.2282 1 4 50.75
Daiichi Sankyo Pharma Moberly
2007 [83]
Celecoxib NSAID 304 TOTPAR 4 – 2 3 50.67
Pﬁzer Cheung 2007
[17]
Celecoxib NSAID 171 TOTPAR 24 1.285 2 2 42.75
Pﬁzer Saito 2012
[96]
NCT01062113 Celecoxib NSAID 255 Efﬁcacy rate (5) of
patient impression
– 22 4 2.90
Merck Gottesdiener
1999 [49]
[5,5-dimethyl-3-(2-isopropoxy)-4-(4-
methanesulfonylphenyl)-2(5H)-furanone]
NSAID 196 TOTPAR 8* 1.634 1 – –
Merck Chang 2004
[15]
Etoricoxib NSAID 225 TOTPAR 6 1.7992 1 – –
Merck Malmstrom
2005 [72]
Etoricoxib NSAID 302 TOTPAR 6 1.7933 1 1 302.00
Merck NCT00694369 Etoricoxib NSAID 588 TOTPAR 6 1.8435 – 6 –
Merck Malmstrom
2004 [76]
Etoricoxib NSAID 398 TOTPAR 8 1.9501 1 5 79.60
Merck Malmstrom
2004 [75]
Etoricoxib NSAID 201 TOTPAR 8 1.7901 1 – –
King Pharmaceuticals
and GlaxoSmithKline
Varner 2009
[117]
NCT00114049 GW406381 NSAID 300 SPID 8 0.9524 1 4 75.00
Iroko Pharmaceuticals NCT00985439 Diclofenac NSAID 202 TOTPAR 12 0.8505 1 3 67.33
Novartis Kubitzek
2003 [66]
Diclofenac NSAID 245 Average pain relief 1 1.2354 – – –
Forest Laboratories Hersh 2004
[53]
ProSorb diclofenac NSAID 265 SPID 3 1.9382 6 – –
Xanodyne
Pharmaceuticals
Zuniga 2010
[125]
Diclofenac NSAID 249 SPID 6 – 7 – –
Javelin Pharmaceuticals Leeson 2007
[67]
Diclofenac NSAID 155 TOTPAR 4 3.0049 1 – –
Javelin Pharmaceuticals Christensen
2011 [18]
Diclofenac NSAID 353 TOTPAR 6 1.8559 3 – –
Pﬁzer NCT00913627 Ibuprofen NSAID 196 SPID 12 – 1 3 65.33
SCOLR Pharma NCT00707057 Ibuprofen Extended-release NSAID 256 SPID 12 0.9608 1 4 64.00
Lutipold Pharma NCT01356225 Intranasal ketorolac NSAID 80 SPID 8 – 1 1 80.00
Merck Schwartz
2007 [98]
MK-0703 NSAID 121 TOTPAR 8 1.3353 1 5 24.20
Bayer NCT00720057 Naproxen sodium Extended-release NSAID 312 SPID 24 1.296 3 2 52.00
Bayer NCT01389284 Naproxen sodium Extended-release NSAID 300 SPID 24 1.086 1 3 100.00
Merck Daniels 2006
[25]
NCT00092300 Rofecoxib NSAID 450 TOTPAR 12 1.9896 – 4 –
Merck Chang 2001
[16]
Rofecoxib NSAID 393 TOTPAR 6 1.3093 1 – –
Merck Chang 2004
[13]
NCT00092313 Rofecoxib NSAID 271 TOTPAR 6 1.4959 2 3 45.17
Merck Desjardin
2007 [30]
NCT00092326 Rofecoxib NSAID 270 TOTPAR 6 1.6662 2 3 45.00
Merck Daniels 2006 NCT00092339 Rofecoxib NSAID 125 TOTPAR 12 1.4159 1 4 31.25
(continued on next page)
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Table 1 (continued)
Sponsor Source Trial
identiﬁcation
Drug Drug
type
N Primary endpoint Standardized
effect size
Number
of sites
Duration of
study (months)
Enrollment rate
(subjects/center/
month)
[25]
Merck Malmstrom
2002 [74]
Rofecoxib NSAID 482 TOTPAR 8 1.6824 1 – –
Merck Korn 2004
[64]
Rofecoxib NSAID 212 TOTPAR 6 1.276 1 2 106.00
Merck Malmstrom
1999 [73]
Rofecoxib NSAID 272 TOTPAR 8 1.5525 1 – –
Merck Chang 2002
[14]
Rofecoxib NSAID 305 TOTPAR 8* 1.63 4 – –
Reckitt Benckiser
Healthcare
NCT01229449 Ibuprofen/acetaminophen NSAID/
other
678 SPRID 12 – 1 8 84.75
Reckitt Benckiser
Healthcare
Mehlisch
2010 [80]
Ibuprofen+paracetamol NSAID/
other
234 SPRID 8 2.1402 2 2 58.50
Reckitt Benckiser
Healthcare
Mehlisch
2010 [81]
Ibuprofen+paracetamol NSAID/
other
735 SPRID 8 – 3 11 22.27
Reckitt Benckiser
Healthcare
Daniels 2011
[26]
Ibuprofen+paracetamol NSAID/
other
678 SPRID 12 4.6 3 7 32.29
Bristol-Myer Squibb Desjardin
2000 [31]
Butorphanol Opioid 151 SPID 6* 0.7578 2 – –
Intranasal Technology Wermeling
2005 [122]
Butorphanol Opioid 60 SPID 6* 0.6784 1 – –
Javelin Pharmaceuticals Christensen
2008 [19]
NCT00390312 Intranasal morphine Opioid 225 TOTPAR 2 – 2 2 56.25
Grunenthal Kleinert 2008
[63]
Tapentadol Opioid 400 TOTPAR 8 1.4325 2 – –
Forest Laboratories Litkowski
2005 [68]
Combo oxycodone/ibuprofen Opioid/
NSAID
249 TOTPAR 6* 1.6659 3 – –
Forest Laboratories van Dyke
2004 [116]
OXY-MD-05 Combo oxycodone/ibuprofen Opioid/
NSAID
498 TOTPAR 6* 1.3129 3 – –
Forest Laboratories OXY-MD-06 Combo oxycodone/ibuprofen Opioid/
NSAID
676 TOTPAR 6* 1.6986 – – –
Ortho-McNeil
Pharmaceuticals
Fricke 2002
[41]
Tramadol/acetaminophen Opioid/
other
200 TOTPAR 4* 0.9693 1 – –
Ortho-McNeil
Pharmaceuticals
Fricke 2004
[40]
NCT00236483 Tramadol/acetaminophen Opioid/
other
456 TOTPAR 3* 1.3776 1 3 152.00
Bayer Health Care Gatoulis
2012 [44]
Acetaminophen with codeine Opioid/
other
302 SPID 6 0.7328 – – –
McNeil PPC NCT01115673 Acetaminophen Other 540 SPRID 6 1.3656 1 7 77.14
Array BioPharma NCT00663767 ARRY-371797 Other 250 TOTPAR 6 – 2 2 62.50
GlaxoSmithKline NCT01082081 Paracetamol Other 350 SPRID 6 – 2 5 35.00
Bristol-Myer Squibb Moller 2005
[84]
Paracetamol Other 152 TOTPAR 6 1.0772 1 3 50.67
Baxter Healthcare Corp NCT00406679 Paracetamol Other 135 Unknown – 2 11 6.14
GlaxoSmithKline Qi 2012 [89] NCT01075243 Paracetamol Other 440 SPRID 6 – 1 4 110.00
Bristol-Myer Squibb Juhl 2006
[58]
Paracetamol Other 297 TOTPAR 6 1.414 1 10 29.70
Pﬁzer NCT01529346 PF-05089771 Other 235 TOTPAR 6 – 2 6 19.58
Bristol-Myer Squibb Van Aken
2004 [115]
Propacetamol Other 99 TOTPAR 5* 1.0671 1 22 4.50
Average 304.5 1.51 2.2 63.29
MPID = mean pain intensity difference; TOTPAR = total pain relief; SPID = sum pain intensity difference; SPRID = sum of pain intensity difference and total pain relief; PR = pain relief.
* Study presented multiple primary endpoints.
 Not primary endpoint.
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Table 2
Bunionectomy standardized effect size and enrollment rate summary.
Sponsor Source Trial
identiﬁcation
Drug Drug
type
N Primary
endpoint
Standardized
effect size
Number of
sites
Duration of
study (months)
Enrollment rate
(subjects/center/month)
Pharmacia Corp Gimbel 2001 [46] Celecoxib NSAID 418 SPID 8* – 24 5 3.48
Iroko Pharmaceuticals NCT01543685 Indomethacin NSAID 460 SPID 48 – 4 4 28.75
Iroko Pharmaceuticals NCT01462435 Diclofenac NSAID 424 SPID 48 – 4 4 26.50
Xanodyne Daniels 2010 [24] NCT00375934 Diclofenac gel caps NSAID 200 SPID 48 1.2263 4 4 12.50
Xanodyne Zuniga 2010 [125] Diclofenac gel caps NSAID – SPID 3* 1.7048 – – –
Xanodyne Riff 2009 [94] NCT00366444 Diclofenac XP21L NSAID 201 Mean NPRS 48 1.1162 6 2 16.80
Merck Desjardins 2004 [29] NCT00092378 Rofecoxib NSAID 252 TOTPAR 8 0.7789 2 3 42.00
Pharmacia Corporation Desjardins 2002 [32] Valdecoxib NSAID 223 Median time to rescue 0.4418 2 – –
Acura Pharma Daniels 2011 [27] NCT00654069 Acurox Opioid 405 SPID 48 0.5526 6 5 13.50
J&J NCT00609466 CG5503 IR Opioid 291 SPID 48 0.5245 6 5 9.70
Aradigm Corp Thipphawong 2003 [111] Inhaled morphine Opioid 89 SPID 1 0.9017 2 2 22.25
Javelin Pharmaceuticals Stoker 2008 [110] Intranasal morphine Opioid 187 TOTPAR 4 – – – –
QRxPharma NCT01280331 MoxDuo Opioid 375 Difference in desaturation events 48 – 4 3 31.25
QRxPharma Richards 2011 [92] MoxDuo Opioid 197 SPID 24 – 6 2 16.42
QRxPharma NCT00831051 Q8003 (MoxDuo) Opioid 197 PID 48 – 6 5 32.83
QRxPharma NCT01016808 Q8003 (MoxDuo) Opioid 522 PID 48 – 5 3 34.80
Grunenthal GmbH NCT00806247 Tapentadol Opioid 480 SPRID 12 – – 7 –
Grunenthal GmbH NCT01435577 Tapentadol Opioid 177 SPID 24 – 1 5 35.40
J&J Weber poster 2006 Tapentadol Opioid – TOTPAR 8 1.2592 – – –
J&J Daniels 2009 [28] NCT00364247 Tapentadol Opioid 602 SPID 48 1.2903 5 9 13.40
J&J Daniels 2009 [23] NCT00613938 Tapentadol Opioid 901 SPID 48 0.9105 3 8 37.50
J&J Stegmann 2008 [109] Tapentadol IR Opioid 269 SPI 24 (day 3) 0.7703 3 – –
AbbVie NCT01333722 Hydrocodone/Ace ER Opioid/
other
99 SPID 12 – 3 2 16.50
Abbott Laboratories NCT00402792 Hydrocodone/Ace ER Opioid/
other
150 SPID 12 – 5 4 7.50
Abbott Laboratories NCT00404222 Hydrocodone/Ace ER Opioid/
other
90 SPID 12 – 3 3 10.00
Abbott Laboratories NCT00404391 Hydrocodone/Ace ER Opioid/
other
210 TOTPAR 12 – 4 5 10.50
AbbVie NCT01038609 Hydrocodone/Ace ER Opioid/
other
250 SPID 48 – 4 5 12.50
Mallinckrodt NCT01484652 Cov795 Opioid/
other
329 SPID 48 – 5 9 7.31
Pacira Pharmaceuticals Golf 2011 [47] NCT00890682 DepoBupivacaine Other 193 AUC NPRS 24 0.4705 4 5 9.70
AbbVie NCT00872885 GRT6005 Other 258 SPID 2 to 10 – 1 5 51.60
Merck Wang 2010 [121] NCT00601458 Pregabalin Other 256 PCA hydromorphone use 24 – 1 6 16.67
QRxPharma NCT01206595 SKY0402 Other 58 Time to ﬁrst use of supplemental medication 96 – 4 12 1.21
Average 292.1 0.92 4.5 20.0
NPRS = numerical pain rating scale; TOTPAR = total pain relief; PID = pain intensity difference; SPI = sum of pain intensity; SPID = sum pain intensity difference; SPRID = sum of pain intensity difference and total pain relief; PR = pain relief;
PCA = patient-controlled analgesia; AUC = area under the curve.
* Study presented multiple primary endpoints.
 Denotes not primary endpoint.
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Table 3
Joint replacement surgery standardized effect size and enrollment rate summary.
Sponsor Source Surgery
type
Trial identiﬁcation Drug Drug
type
N Primary endpoint Standardized
effect size
Number of
sites
Duration of study
(months)
Enrollment rate
(subject/center/
months)
Pﬁzer TKA NCT00633386 Celecoxib NSAID 200 Analgesic use 24 – 9 6 3.70
Pﬁzer TKA NCT00633438 Celecoxib NSAID 204 Analgesic use 24 – 18 5 2.27
Merck Rasmussen 2005
[90]
TKA/THA Etoricoxib NSAID 228 TOTPAR 8 0.5348 8 – –
Merck TKA NCT00820027 Etoricoxib NSAID 776 Average PID at rest
3 days
– – 24 –
Cumberland Pharmaceuticals Singla 2010 [104] TKA/THA NCT00470600 Ibuprofen NSAID 185 AUC Visual analog
scale upon
movement 6 to 28
0.8298 8 16 1.45
Javelin Pharmaceuticals Orthopedic NCT00507026 Intravenous
diclofenac
NSAID 277 SPID 24 – 8 5 6.93
Novartis Chan 2005 [12] TKA/THA Lumiracoxib NSAID 180 SPID 8 0.5072 14 – –
Pharmacia Corporation Hubbard 2003
[54]
TKA Parecoxib NSAID 195 Analgesic consumption
24*
– 10 8 2.44
Merck Reicin 2001 [91] TKA/THA Rofecoxib NSAID 218 TOTPAR 8 0.5673 9 – –
Pharmacia/Pﬁzer Camu 2002 [10] THA Valdecoxib NSAID 217 Morphine consumption
until 2nd dose*
0.6819 12 – –
QRxPharma TKA NCT01055015 Q8003 Opioid 141 PID 48 – 10 10 1.41
AcelRx Pharmaceuticals TKA NCT00612534 Oral sufentanil Opioid 188 PID 12 – 1 7 26.86
Endo Pharmaceuticals Gimbel 2004 [45] TKA/THA Opana 3203-04 Oxymorphone Opioid 300 TOTPAR 8* 0.72 29 – –
Endo Pharmaceuticals TKA/THA Opana 3203-05 Oxymorphone Opioid 324 TOTPAR 8 0.6081 9 – –
Endo Pharmaceuticals Ahdieh 2004 [1] TKA 2102-012 Oxymorphone Opioid 126 TOTPAR 12 0.4125 – – –
QRxPharma TKA/THA NCT00818493 Q8003 Opioid 44 PID 48 – 4 5 2.20
AcelRx Pharmaceuticals TKA NCT00859313 Sufentanil
NanoTab
Opioid 30 Percent of patients
without device failure
12
– 3 4 2.50
J&J Hartrick 2009 [51] TKA/THA NCT00361582 Tapentadol Opioid 666 SPID 5 days 0.464 – 10 –
QRx Pharma Joppich 2012 [57] THA Eudra CT-No.2008-
008527-14
Intravenous
morphine +
oxycodone
Opioid 41 SPID 65 minutes 0.5458 2 10 2.05
Forest Laboratories TKA/THA OXY-MD-07 Combunox Opioid/
NSAID
TOTPAR 6 0.9186 – – –
Anesiva Inc.; Arcion Therapeutics TKA 114-01P 4974 Capsaicin Other 217 AUC 48 0.2914 24 – –
Anesiva Inc. THA NCT00683267 4975 Capsaicin Other 118 PI (NRS) 2 days – 14 10 0.84
Skye Pharma Viscusi 2005 [119] THA SKY0401-011 DepoDur Other 200 Total fentanyl use 48 1.2586 23 – –
Skye Pharma Martin 2006 [78] THA DepoDur Other 126 Total fentanyl use 48 1.4734 16 – –
Javelin Pharmaceuticals Orthopedic NCT00709436 Intranasal
ketamine
Other 250 SPID 6 – 16 38 0.41
Cadence Pharmaceuticals Sinatra 2005 [100] TKA/THA RC2103-002 Paracetamol Other 156 TOTPAR 6 0.8923 7 9 2.48
Bristol-Myers Squibb THA NCT00344045 Paracetamol Other 86 Total tramadol
consumption 24
– 5 22 0.78
Baxter Healthcare Corp THA NCT00508495 Paracetamol Other 148 PCA-morphine 6 – 8 7 2.64
Orthopaedic Research & Innovation
Foundation
THA NCT01106001 Periarticular Levo
Bupivicaine
Other 91 Difference in morphine
consumption
– 2 12 3.79
Pﬁzer Unpublished data TKA NCT00442546 Pregabalin Other 307 Mean worst pain 24 0.1379 28 19 0.58
Pacira Pharmaceuticals Bramlett 2012 [8] TKA NCT00485693 SKY0402 Other 138 AUC NRS-A 4 days – 10 26 5.31
Pacira Pharmaceuticals TKA NCT00745290 SKY0402 Other 251 AUC NRS-A 72 – 19 5 2.64
KAI Pharmaceuticals TKA/THA NCT01015235 KAI-1678 Other 90 SPID 4 – 1 14 6.43
Average 209.9 0.68 10.9 3.9
TKA = Total Knee Arthroplasty; THA = Total Hip Arthroplasty; NSAID = nonsteroidal anti-inﬂammatory drug; TOTPAR = total pain relief; PID = pain intensity difference; SPI = sum of pain intensity; SPID = sum pain intensity
difference; AUC = area under the curve; NRS = numerical rating scale.
* Study presented multiple primary endpoints.
448
N
.K
.Singla
et
al./PA
IN

155
(2014)
441–
456
Table 4
Soft tissue surgery standardized effect size and enrollment rate summary.
Sponsor Source Surgery type Trial
identiﬁcation
Drug Drug
type
N Primary endpoint Standardized
effect size
Number of
sites
Duration of study
(months)
Enrollment rate
(subjects/center/
month)
Cumberland
Pharmaceuticals
Kroll 2011 [65] Hysterectomy NCT00225732 IV ibuprofen NSAID 319 Mean morphine
consumption 24
0.2807 10 36 0.89
Javelin Pharmaceuticals Gan 2012 [43] Abdominal NCT00448110 IV diclofenac NSAID 331 SPID 48 – 16 18 1.15
Merck Fleckenstein 2010 [39] Abdominal NCT00716833 Etoricoxib NSAID 87 Morphine use 48 – 2 58 0.75
Merck Viscusi 2012 [118] Hysterectomy NCT00788710 Etoricoxib NSAID 430 Average PI 3 days 0.4971 39 21 0.53
Merck Sinatra 2006 [99] Gynecological Rofecoxib NSAID 164 Average total dose of
opioid 5 days
0.4467 7 – –
Pﬁzer Cholecystectomy NCT00661635 Valdecoxib NSAID 490 SPI 24 – 65 8 0.94
Pﬁzer Prostatectomy NCT00346268 Parecoxib NSAID 105 Cumulative morphine
consumption 24
0.4155 4 45 0.58
Pﬁzer Malan 2005 [71] Gynecological Paracoxib NSAID 264 TOTPAR 8 1.2529 – – –
ROXRO Pharma Singla 2010 [105] Abdominal NCT00266786 Ketorolac NSAID 321 SPID 1 day 0.2471 6 14 3.82
Endo Pharmaceuticals Aqua 2007 [3] Abdominal NCT00226395 Oxymorphone Opioid 320 TOTPAR 6* 0.5338 21 11 1.39
J&J/Grunenthal GmbH Hysterectomy NCT00478023 Tapentadol Opioid 854 SPID 24 0.5561 52 9 0.68
Cara Therapeutics Hysterectomy NCT00877799 CR845 Opioid 114 PI at rest after surgery – 12 10 0.95
Forest Pharmaceuticals Singla 2005 [103] Abdominal OXY-MD-10 Combination
Oxycodone/
ibuprofen
Opioid/
NSAID
456 TOTPAR 6 0.7933 26 – –
Knoll Pharmaceuticals Palangio 2000 [88] Gynecological Hydrocodone with
ibuprofen
Opioid/
NSAID
180 Mean TOTPAR 8 1.4821 1 – –
Cadence Pharmaceuticals Gynecological NCT00399568 IV acetaminophen Other 331 SPI 24 0.115 27 10 1.23
Cadence Pharmaceuticals Wininger 2010 [123] Abdominal NCT00564486 IV acetaminophen Other 244 SPID 24 0.2699 17 10 1.44
DURECT Corp Hysterectomy NCT00993226 SABER-bupivacaine Other 115 PI 3 days – 14 7 1.17
Endo Pharmaceuticals Carvalho 2005 [11] Cesarean delivery DepoDur Other 79 Total opioid use 48 – 8 – –
SkyePharma Gambling 2005 [42] Abdominal DepoDur Other 541 Total IV fentanyl 48 – 55 – –
Innocoll Technologies Hysterectomy NCT00624910 CollaRx bupivacaine Other 54 Opioid rescue 24 – 1 9 6.00
Innocoll Technologies Hysterectomy NCT00749749 CollaRx bupivacaine Other 27 Opioid rescue 24 – 1 3 9.00
Pacira Pharmaceuticals Herniorrhaphy NCT00485433 DepoBupivacaine Other 98 AUC NRS-A 72 – 7 6 2.33
Pacira Pharmaceuticals Herniorrhaphy NCT01203644 DepoBupivacaine Other 76 Time to 1st supplemental
pain medication 96
– 16 13 0.37
Pacira Pharmaceuticals Gorﬁne 2011 [48] Hemorrhoidectomy NCT00890721 DepoBupivacaine Other 189 AUC 72 0.5867 13 8 1.90
Pacira Pharmaceuticals Hemorrhoidectomy NCT00529126 DepoBupivacaine Other 100 AUC 72 – 7 3 4.76
Pacira Pharmaceuticals Hemorrhoidectomy NCT00744848 DepoBupivacaine Other 220 AUC 96 – 20 6 1.83
Pﬁzer Mathiesen 2009 [79] Hysterectomy NCT00209495 Pregabalin Other 130 Morphine consumption 24* – 2 29 2.24
Pﬁzer Paech 2007 [87] Gynecologic Pregabalin Other 99 Predischarge pain 0.0952 1 7 12.86
Pﬁzer Unpublished data Hysterectomy NCT00468845 Pregabalin Other 501 Mean worst pain 24 0.0902 42 35 0.34
Pﬁzer Unpublished data Herniorrhaphy NCT00551135 Pregabalin Other 425 Mean worst pain 24 0.2078 42 20 0.51
Average 261.3 0.50 18.4 2.4
PI = pain intensity; TOTPAR = total pain relief; SPID = sum pain intensity difference; SPI = summed pain intensity; AUC = area under the curve; IV = intravenous.
* Multiple primary endpoints.
 Not primary endpoint.
 Study was terminated.
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Table 5
Demographics by surgical model.
Dental Bunion JRS STS
Total subjects 13,875 5073 3116 4357
Average age (years) 22.2 43.4 59.2 44.6
Sex (%)
Male 40 16 45 22
Female 60 84 55 78
Race
White 77 63 91 69
Hispanic 9 15 1 4
African American 5 16 6 17
Other 9 6 2 10
Baseline pain (%)
Moderate 65 46 49 78
Severe 35 54 51 22
Average duration of surgery (minutes) 17.7 29.8 70.9 82.3
JRS = joint replacement surgery; STS = soft tissue surgery.
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fect is challenging because a signiﬁcant portion of patients no long-
er require analgesic therapy [9,94]. Bunionectomy is typically an
outpatient procedure. Therefore a common misperception is that
the surgery is not painful, and as such is ill-suited to the evaluation
of intravenous analgesics. In fact, when performed under experi-
mental conditions, the anesthesia protocol for bunionectomy can
be manipulated so that subjects experience the amount of pain
requisite for multiple-day experiments, but not so much pain that
the postoperative course becomes unethical or below a reasonable
standard of care.
3.2.2. Surgical and anesthetic protocol
Surgical inclusion criteria in bunion models are relatively
homogeneous and are not purposefully manipulated to affect the
postoperative pain trajectory (in contrast to the manipulations uti-
lized in the dental model that are described in Fig. 2). Generally,
only subjects with type 2 hallux valgus deformity requiring ﬁrst
unilateral metatarsal head osteotomies are enrolled. Subjects with
a type 3 deformity requiring a base wedge osteotomy (a more
extensive procedure) or those requiring concomitant surgery such
as hammertoe repair are excluded [29,94].
Alterations in the anesthetic protocol are the main experi-
mental manipulation utilized in the model primarily because
the intraoperative inﬁltration of local anesthetics and perfor-
mance of any concomitant nerve block can predictably alter
the postoperative pain course. That being the case, the anes-
thetic regimen dictated by each protocol is distinct and is specif-
ically designed to optimize the pain trajectory required for the
experiment. Once selected, anesthetic protocols tend to be
prescriptive and allow few discretionary modiﬁcations based
on local practice.
Duration and density of postoperative analgesia secondary to
local anesthetic inﬁltration are inﬂuenced by altering the type
and volume of intraoperative inﬁltration (ie, 20 mL of long-acting
bupivacaine vs 10 mL of shorter-acting lidocaine) [2,47,94]. In
some instances, popliteal catheters are utilized to continuously
infuse local anesthetic near the sciatic nerve to provide dense
anesthesia over a prolonged period of time [55,95,102]. These
catheters are used when there is a desire to delay the onset of
postoperative pain until 18 or 24 hours after the initial surgical
insult. A delayed pain trajectory is desirable when there is con-
cern that the otherwise unfettered pain intensity from bunionec-
tomy in the early postoperative hours (0 to 24 hours after
surgery) will overwhelm the experimental agent, and as such
the 24+ hour pain trajectory is preferred. In these circumstances,
randomization is delayed until after the nerve block catheter isremoved and the patient subsequently develops moderate or se-
vere pain intensity.
3.2.3. Enrollment rate
Similar to the dental model, the bunionectomy model generally
relies on the research grant to subsidize the cost of the surgical
procedure. As such, the 2 models share several characteristics: ra-
pid subject acquisition (20 bunion subjects/center/month) at a few
centers (average 4.5) that primarily focus on analgesic research
(Fig. 3, Table 2).
3.2.4. Assay sensitivity
Average bunion SES was 0.92; 39% less than dental, 35% greater
than JRS, and 84% greater than STS (Fig. 4). Bunionectomy and JRS
share a similar pathophysiology, yet SES in bunionectomy is signif-
icantly higher. The pain response in both surgical models emanates
primarily from bony injury, and JRS is the more painful of the two.
Why then is the SES in bunionectomy greater? We speculate that
the conditions under which bunionectomy studies are performed
(few centers, trained staff, control of standard of care confounders)
reduce experimental error.
3.2.5. Model limitations
Similar to the dental model, the main criticism of the bunion
model is its lack of clinical relevance. In contrast to STS or JRS, bun-
ionectomy performed in clinical practice (outside of research set-
tings) is an outpatient procedure performed primarily on young
(mean age 43.4) women (84%; Table 5), that can be managed with
copious intraoperative local inﬁltration and oral analgesics [77,97].
If one is investigating a potent intravenous analgesic meant pri-
marily for relief of pain in elderly hospitalized subjects, clinicians
and regulators have argued that efﬁcacy and safety ﬁndings in
the bunionectomy model are not generalizable.
3.3. Joint replacement surgery model
3.3.1. Introduction
Over 1million patients undergo joint replacement surgery (total
knee or total hip arthroplasty) annually [108]. These surgeries are
generally performed on older (mean age 70.9) [56,120] individuals
who have signiﬁcant concomitant pathologies and are preopera-
tively on several prescription drugs [38]. Postoperatively, patients
are hospitalizedwith an average length of stay of 5 days [7,52]. Dur-
ing this inpatient stay, multiple drugs and techniques are used to
amelioratepostsurgical pain [101]. After approval, potent analgesics
intended for inpatient use will frequently be administered (1) to
subjects who match the demographics of those included in the JRS
model and (2) in institutions similar to those in which JRS subjects
have surgery and convalesce. Therefore, the model is regarded as
clinically relevant by regulators and prescribing physicians.
3.3.2. Surgical and anesthetic protocol
Because of their frequency, joint replacements represent an
important service line in most multispecialty hospital environ-
ments. Local standards are agreed upon and protocolized by a di-
verse care team, with signiﬁcant attention focused on improving
the patient’s postoperative pain experience. Every local standard
is unique because the standard depends heavily on the human
and technical resources available at the institution that creates it.
Therefore, perioperative analgesic management of joint replace-
ment subjects between institutions is variable, and within institu-
tions, dogmatic. Research protocols that attempt to control
analgesic confounders are in many instances in conﬂict with insti-
tutional practices.
There is signiﬁcant heterogeneity in the surgical techniques
used to accomplish joint replacement [86]. For hip replacement
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approach reduce tissue damage, postoperative pain, and length of
hospital stay [61,106]. Standard of care anesthetic techniques are
also heterogeneous. The availability of ultrasound guidance is
increasing the popularity of femoral nerve blocks in total knee
replacement surgery. In both knee and hip arthroplasty,multimodal
analgesic therapy and neuraxial anesthesia are in common use
[70,101].
Successful JRS studies generally attempt to control surgical and
anesthetic confounders by disallowing subjects scheduled to re-
ceive minimally invasive surgeries, bilateral joint replacement,
revision arthroplasties, nerve blocks, epidural analgesia, and anal-
gesic adjuncts (eg, nonsteroidal anti-inﬂammatory drugs, pregaba-
lin, acetaminophen) [1,10,90,119]. Protocols also attempt to
minimize variability by standardizing institutional confounders
such as (1) use of perioperative ice and cooling devices, (2) timing
and frequency of physical therapy, and (3) use of continuous pas-
sive range of motion devices [45,91].
3.3.3. Enrollment rate
Enrollment into JRS studies is slower than enrollment into
dental impaction or bunionectomy studies. Only 3.9 subjects
per center per month were recruited into JRS protocols, necessi-
tating a large number of centers (average 11) to accrue subjects
in a timely fashion (Fig. 3). Dental and bunion enrollment is fas-
ter than JRS for the following reasons: (1) JRS is an expensive
inpatient surgery that cannot practically be subsidized by the re-
search grant, (2) JRS patients identiﬁed for the study are other-
wise scheduled for elective surgery at participating institutions,
performance of the surgery is not predicated on study participa-
tion, (3) therefore, subjects in JRS protocols must be garnered
from hospital databases or physician ofﬁces (not recruited via
advertisement as with bunion and dental subjects), and conse-
quently (4) funneling subjects into nonhospital-based standalone
research institutions is impractical.
3.3.4. Assay sensitivity
Although in our review the average SES for JRS was 0.68 (Fig. 4),
the true value is probably signiﬁcantly lower and has been inﬂated
here secondary to publication bias (see Section 4 for details). The
average sample size for JRS studies reviewed was 209. In a 2-arm
study with a total enrollment of 209, if one desires 90% power to
detect an alpha of 0.05, an SES of at least 0.45 is required. When
average SES values near 0.45 in studies with 209 subjects, the risk
of trial failure is high. If our reported average JRS SES of 0.68 is in
fact inﬂated, the high frequency of late-phase JRS failures is an
unfortunate but predictable consequence.
3.3.5. Model limitations
To adequately care for postsurgical patients, hospitals have pro-
tocols and norms outside the research study that dictate standard of
care perioperative treatment [6,70,124]. These institutional norms,
although clinically useful, often introduce analgesic confounders.
The problem is compoundedwhenmultiple research centers are in-
volved with a single project. Slow recruitment rates force programs
to adopt amulticenter approach inorder to complete enrollment in a
reasonable timeframe. As a result, the study protocol is forced to
accommodate a range of local practices and to allow some degree
of surgical and anesthetic variation. These compromises increase
variability, in turn reducing SES.
3.4. Soft tissue surgery model
3.4.1. Introduction
STS represents a diverse group of surgical procedures that are
generally performed on an inpatient basis. As a group, they arecommon and as such are of signiﬁcant clinical interest to regula-
tors and prescribing physicians. Within most studies, the speciﬁc
procedure type was not homogenized, forcing us to categorize dis-
parate surgeries into this model. Our a priori deﬁnition of STS was
abdominal or pelvic surgeries not involving signiﬁcant bony injury.
Hysterectomy, cholecystectomy, cesarean section, herniorrhaphy,
hemorrhoidectomy, and prostatectomy were all represented. The
surgical insult and recovery from this incongruent group of proce-
dures is heterogeneous, confounding our analysis.
3.4.2. Surgical and anesthetic protocol
In the discussion of previous surgical models, speciﬁc surgical
and anesthetic comparisons were possible because the surgery
types were relatively homogeneous. In STS, the surgical and anes-
thetic paradigmsare so variable [48,87,99] thatmeaningful compar-
isons could not be made. One consistent feature throughout most
STS studies was that an attempt was made to control for laparo-
scopic vs open approaches [3,65,71,118]; either only laparoscopic
or only open procedures were allowed. Although the dental and
bunionmodels altered surgical and anestheticmanagement to opti-
mize experimental conditions, precise manipulations of this sort
werenot attempted in STS. Insteadof optimization, focuswasplaced
on surgical standardization and the avoidance of obvious perioper-
ative confounders such as epidural analgesia, neuraxial opioids,
adjuvant medications, nerve blocks, and inﬁltration analgesia (both
single-dose and via continuous infusion) [39,65,103,105].
3.4.3. Enrollment rate
STS has the slowest enrollment rate of all models considered
(Fig. 3). It suffers from the same logistical problems as JRS, inability
to subsidize procedural costs and therefore funnel patients into se-
lect units. The problem for STS is compounded by the fact that re-
cent advances in laparoscopic surgery have divided the already
thin ﬁeld of potential candidates into 2 categories: laparoscopic
and open.
3.4.4. Assay sensitivity
Of all 4 models, STS had the lowest SES values (74%, 54%, and
33% of JRS, bunionectomy, and dental, respectively; Fig. 4). Low
SES values in STS are difﬁcult to attribute squarely to experimental
error because STS is the only soft tissue model examined; dental,
bunion, and JRS are all regarded as bony models. Perhaps the path-
ophysiology of STS is unique, such that our current spectrum of
analgesics is actually, not artiﬁcially, less effective against soft tis-
sue pain. In STS, pain results not only from soft tissue trauma, but
also from ileus, bloating, cramping, and insufﬂation-related dia-
phragmatic irritation [5,85].
3.4.5. Model limitations
Although low SES values in STS may be attributable to unique
pathophysiology, STS is subject to the same institutional confound-
ers as JRS. Both models generally must be performed inside multi-
specialty hospitals and cannot be executed within controlled
research-centric units. Like JRS, slow recruitment in STS necessi-
tates a multicenter approach. Often, investigators within an insti-
tution are compelled to pool their resources and enroll subjects
emanating from several surgical practices. Although this process
can be positive and collaborative, it increases variability. Finally,
the episodic nature of cramps and gas pain in STS may lead to spu-
rious analgesic measurements [85].
4. Discussion
Our conclusions have relied heavily on SES data. Although study
design and conduct impact SES, the inherent efﬁcacy of the study
Fig. 5. Standardized effect size in speciﬁc surgical models with molecule, dose, and route held constant. Combunox (oxycodone HCl/ibuprofen), etoricoxib, intravenous
ibuprofen, and paracetamol were not studied in the bunionectomy model. ⁄Average of multiple SES values if more than 1 study was conducted utilizing a particular model.
JRS = joint replacement surgery; STS = soft tissue surgery; PO = oral; IV = intravenous; SES = standardized effect size.
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rearranged a subset of our data to control for molecule, dose, and
route of administration (Fig. 5). We found 2 molecules that have
been studied in all 4 surgical models and 4 molecules that have
been studied in at least 3 models. We made no statistical compar-
isons, but the numerical trend is apparent; a signiﬁcant decrease in
assay sensitivity from the dental and bunion models (well-con-
trolled investigations performed at few centers) to the JRS and
STS models (clinically confounded investigations performed at
many centers).
In our primary analysis, SES values were averaged, not weighted
based on study enrollment. Meta-analytical techniques that at-
tempt to estimate the true treatment effect of a drug in a popula-
tion must consider how many patients were enrolled in each study
because there is an assumption that all experiments are subject to
the same degree of experimental error. Variations in SES values be-
tween studies are assumed to be random. Therefore, studies with
higher sample sizes are considered to be more reliable (less ran-
dom) and given more weight. Our premise was the opposite; we
assumed that SES variations were not random but could in fact
be systematically predicted. Here, each study SES represented a
best-effort scenario within each surgical model, and an averaging
of all of these best-effort attempts without regard to sample size
was therefore considered to be a more accurate way to evaluate
experimental error.
The SES analysis did not attempt to control for number of
centers, randomization schemes, endpoint characteristics, impu-
tation methods, or rescue paradigms. If the purpose of the sys-
tematic review had been to quantitatively measure the
confounding characteristics of speciﬁc study features, a multivar-
iate analysis would have been appropriate. Here, an attempt was
made to compare surgical models, not speciﬁc study features,with the important output being SES trends rather than absolute
values.
We chose to limit our review to data published or presented
after 1998. Numerous acute pain studies with valuable information
were performed before this date. However, the surgical approach,
anesthetic management, and perioperative care of patients under-
going JRS and STS have evolved signiﬁcantly over the past 15 years.
The models are inherently different than they once were; there-
fore, inclusion of studies performed before this date would have
confounded our analysis. Additionally, we chose to include only
industry-sponsored studies because a priori we hypothesized that
sponsorship status would affect study methodology and SES
trends. Post-hoc, we reanalyzed our data and found that the inclu-
sion of nonindustry-sponsored studies did not materially change
our results (data on ﬁle).
It is likely that publication bias inﬂated our SES results. Stud-
ies that report positive ﬁndings tend to be published more fre-
quently than studies that report negative ﬁndings [107].
Negative studies have SES values that fall short of predictions
made during the design phase. Our investigation relied heavily
on published studies. Of 89 studies that met SES criteria, 86
(97%) were positive. The speciﬁc percentage of acute pain inves-
tigations that yield positive results is unknown, but 97% is
clearly an overestimation.
It is probable that recruitment data presented are also in-
ﬂated. The subject per center per month calculation is predicated
on the number of centers that were reported in the relevant data
source. In late-phase studies, approximately 27% of centers fail
to enroll any patients [59]. Nonenrolling centers are generally
not included in the ﬁnal tally when total number of centers is
disclosed. If true, our subject/center/month quotient would have
been artiﬁcially increased. Similar to the SES analysis, trends are
the reliable output.
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Surgical procedures have unique clinical characteristics that
inﬂuence the degree to which their experimental properties can
be idealized. We found that the dental impaction and bunionec-
tomy models had higher assay sensitivity than the JRS and STS
models. It is probable that this ﬁnding is secondary to the superior
experimental conditions under which the dental and bunion mod-
els are executed (utilization of few centers that have the ability to
limit surgical, anesthetic, and postoperative variability). Joint
replacement and soft tissue surgery are, in general, complex proce-
dures that require inpatient care. From an experimental standpoint
the hospital is a nonideal environment because it is confounded by
the effects of multispecialty care.
Over the past 60 years, pioneers in acute pain research have
posed, debated, and resolved several key methodological ques-
tions. The knowledge garnered through their purposeful study
has been successfully applied to the dental and bunion models.
However, a signiﬁcant gap exists in the application of these princi-
ples to the JRS and STS models. Certain groups are experimenting
with techniques that may improve the assay sensitivity of JRS
and STS.
Speciﬁcally, an outpatient model for STS that mirrors the exper-
imental conditions of the dental and bunion models is being devel-
oped (subjects recruited through advertisement, cost of surgical
care subsidized with subsequent funneling of participants into re-
search-centric units). Herniorrhaphy, abdominoplasty, and laparo-
scopic cholecystectomy are outpatient soft tissue procedures that
are candidates for model development. If one of these models con-
sistently demonstrates adequate assay sensitivity, it could be uti-
lized to generate drug efﬁcacy data in soft tissue on an
outpatient basis, avoiding the confounding effects of multispecialty
inpatient care.
There are circumstances in which an inpatient environment
should not or cannot be avoided (eg, a new drug administered
via a patient-controlled analgesic device). In these situations we
theorize that several modiﬁcations can be made to hospital-based
experiments that have the potential to improve their assay sensi-
tivity: (1) reducing the number of research centers participating
in a single study, (2) limiting the surgical variance by including
only speciﬁc surgeries performed utilizing a consistent technique,
(3) controlling anesthetic management and perioperative care,
(4) training subjects on placebo response and completion of proto-
col-mandated analgesic scales, and (5) education of investigators
and study staff on bias reduction and uniform data gathering
techniques.
Further study will be required to correlate and quantify the spe-
ciﬁc design features that are responsible for degrading assay sensi-
tivity in the JRS and STS models. By implementing and critically
evaluating new techniques, the knowledge garnered from the work
of previous analgesic methodologists may be expanded.
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